GenSight Biologics Announces Availability of Prospectus for New Shares Listing on Euronext Paris

GenSight Biologics, a biopharma company specializing in gene therapies for retinal and central nervous system disorders, announced the release of a prospectus for new shares to be listed on Euronext Paris. Issued on May 7, 2024, the document has received approval from the French financial regulatory body, Autorité des Marchés Financiers (AMF), with the number D.24-0299-A01.

The prospectus comprises the 2023 universal registration document, an amendment to this document, a securities note, and a summary, all of which were made public on the same day. These documents are integral to GenSight’s planned capital increase and trading on the Euronext market, aiming to raise approximately €9.2 million through specialized investor reserved increases and concurrent private placements with attached warrants.

The details of this financial action are available on GenSight’s and the AMF’s websites, ensuring transparency and accessibility for interested parties. The move marks a significant step in the company's efforts to broaden its investor base and secure further funding for its developmental programs targeting debilitating retinal diseases.